Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

Table 3 Summary DLQI and pruritus VAS scores at week 16

Patient-reported outcome	Placebo (n=88)	Apremilast BID
		10 mg (n=89)	20 mg (n=86)	30 mg (n=88)
DLQI
Baseline	10.7 ± 6.7	10.8 ± 6.3	11.6 ± 7.0	10.6 ± 6.2
Week 16	8.6 ± 7.6	7.6 ± 6.3	5.8 ± 6.0	6.0 ± 6.2
Change from baseline	−1.9 ± 5.2	−3.2 ± 6.0	−5.9 ± 6.7*	−4.4 ± 5.1*
Pruritus VAS
Baseline	55.5 ± 25.5	54.1 ± 23.5	58.3 ± 26.7	55.3 ± 25.5
Week 16	45.6 ± 30.2	39.0 ± 27.8	35.2 ± 29.2	31.6 ± 30.0
Percent change from baseline	−6.1 ± 76.4	−10.2 ± 100.8	−35.5 ± 66.0*	−43.7 ± 46.8*

*P≤0.005 vs placebo.
Values are mean ± SD. DLQI, Dermatology Life Quality Index; VAS, visual analog scale.

ISSN: 1477-7525